Milan

• A Phase 3 Randomized Study Comparing Talquetamab SC in Combination With Daratumumab SC and Pomalidomide (Tal-DP) or Talquetamab SC in Combin … Ended recruitment
  2023-503467-41-00 5 2022-10-12 Relapsed or Refractory Multiple Myeloma
• A Study to Assess Adverse Events and Change in Disease Activity of Intravenously (IV) Infused Etentamig (ABBV-383) in Combination With Anti- … Ended recruitment
  2023-506871-88-00 3 2022-10-07 Relapsed/Refractory Multiple Myeloma
• A FIRST-IN-HUMAN (FIH) STUDY OF IDRX-42 IN PARTICIPANTS WITH METASTATIC AND/OR UNRESECTABLE GASTROINTESTINAL STROMAL TUMORS (GIST) Ended recruitment
  2024-514930-19-00 9 2022-10-07 metastatic and/or unresectable gastrointestinal stromal tumors (GIST)
• Study of ceralasertib plus durvalumab versus docetaxel for patients with advanced or metastatic non-small cell lung cancer Ended recruitment
  2023-509429-37-00 5 2022-10-03 Advanced or Metastatic Non-Small Cell Lung Cancer
• A randomized, two-armed, single-blind, parallel, active controlled, and non-inferiority clinical trial to Compare Efficacy and Safety of ant … Ended recruitment
  2024-515557-22-00 6 2022-10-01 Juvenile Idiopathic Arthritis
• Master Protocol for Encorafenib/Binimetinib Continuation Sub-Studies (FLOTILLA Study) Ended recruitment
  2023-509408-13-00 6 2022-09-20 Solid tumors
• SURE-02_An open label, single-arm, phase 2 study of perioperative pembrolizumab plus sacituzumab govitecan, and bladder-saving approach, for … Ended recruitment
  2024-514569-20-00 4 2022-09-15 muscle-invasive bladder cancer
• A Study to Evaluate Higher Dose (HD) Nusinersen (BIIB058) in Participants With Spinal Muscular Atrophy Previously Treated With Risdiplam (AS … Ended recruitment
  2023-505639-11-00 5 2022-09-14 Spinal Muscular Atrophy
• Study of Sacituzumab Govitecan-hziy and Pembrolizumab Versus Treatment of Physician's Choice and Pembrolizumab in Patients With Previously U … Ended recruitment
  2023-504194-21-00 5 2022-09-13 PD-L1 Positive Metastatic Triple-Negative Breast Cancer
• Phase 3 Study of Patritumab Deruxtecan Versus Platinum-based Chemotherapy in Metastatic or Locally Advanced EGFRm NSCLC After Failure of EGF … Ended recruitment
  2023-507964-38-00 5 2022-09-01 Metastatic or Locally Advanced Epidermal Growth Factor Receptor-mutate
• Study of Sacituzumab Govitecan-hziy Versus Treatment of Physician's Choice in Patients With Previously Untreated Locally Advanced Inoperable … Ended recruitment
  2023-504195-14-00 5 2022-08-31 PD-L1-negative metastatic triple-negative breast cancer or PD-L1-posit
• A research study to compare somapacitan once a week with Norditropin® once a day in children who need help to grow Ended recruitment
  2023-506927-27-00 5 2022-08-29 Children with short stature either born small for gestational age or w
• Study of DS-1062a with or without Pembrolizumab in Advanced or Metastatic Non-small Cell Lung Cancer without Actionable Genomic Alterations Ended recruitment
  2023-507933-12-00 5 2022-08-18 Advanced or Metastatic Non-small Cell Lung Cancer (NSCLC)
• A Clinical Study of Lazertinib with Subcutaneous Amivantamab Compared with Intravenous Amivantamab in Patients with EGFR-mutated Advanced or … Ended recruitment
  2024-512045-16-00 5 2022-08-18 EGFR-mutated Advanced or Metastatic Non-small Cell Lung Cancer
• Coronary Computed Tomography Study to Assess the Effect of Inclisiran in Addition to Maximally Tolerated Statin Therapy on Atherosclerotic P … Ended recruitment
  2024-511126-31-00 5 2022-08-16 Non-obstructive Coronary Artery Disease
• A Study of an experimental drug, MK-2140 in combination with standard of care chemotherapy in participants with Diffuse Large B-Cell Lymphom … Ended recruitment
  2022-501380-40-00 4 2022-08-10 Diffuse large B-cell lymphoma (DLBCL)
• Pilot phase II study of Selinexor in combination with Ifosfamide, Etoposide and Dexamethasone (SIDE) in patients with relapsed or refractory … Ended recruitment
  2024-513295-18-00 4 2022-08-10 Relapsed or Refractory Peripheral T-cell Lymphomas
• Taletrectinib in ROS1 Positive Lung Cancer Phase 2 Global Study Ended recruitment
  2024-516604-41-00 4 2022-08-08 Non-small Cell Lung Cancer
• Three-arm study of the clinical efficacy, safety and tolerability of ianalumab (VAY736) in patients with active Sjögren’s syndrome Ended recruitment
  2024-511068-10-00 5 2022-08-04 Sjögren’s Syndrome
• A Phase 1b Study of Bleximenib in Combination with AML Directed Therapies for Participants with Acute Myeloid Leukemia Harboring KMT2A or NP … Ended recruitment
  2023-506582-58-00 3 2022-07-21 Acute Myeloid Leukemia
• Study of efficacy, safety and tolerability of ianalumab versus placebo, in combination with SoC therapy, in participants with active lupus n … Ended recruitment
  2023-508559-37-00 5 2022-07-14 Lupus nephritis
• A study to investigate the efficacy and safety of depemokimab compared with mepolizumab in adults with relapsing or refractory Eosinophilic … Ended recruitment
  2023-510019-20-00 5 2022-07-13 Relapsing or refractory Eosinophilic Granulomatosis with Polyangiitis
• A trial to learn how well Dato-DXd works and how safe it is compared to standard chemotherapy in adults with triple-negative breast cancer ( … Ended recruitment
  2023-509260-25-00 5 2022-07-12 Locally Recurrent Inoperable or Metastatic Triple-negative Breast Canc
• A clinical trial to compare the effectiveness and safety of giredestrant with a subcutaneous combination of pertuzumab and trastuzumab versu … Ended recruitment
  2022-500014-26-00 5 2022-06-24 Locally-Advanced unresectable or Metastatic breast cancer (MBC)

Showing 1,513–1,536 of 2,361 trials